UNSPSC 51372306: Hydroxypethidine

This classification denotes an opioid receptor agonist with the molecular formula C15H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W1J43H2B3K, chemically known as 4-piperidinecarboxylic acid, 4-(m-hydroxyphenyl)-1-methyl-, ethyl ester but generally known as hydroxypethidine, which bears US NIH Compound Identifier 61120. European Medicines Agency schedules Hydroxypethidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08079MIG.

UNSPSC 51372306 Hydroxypethidine is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related supply systems procured to support public health and emergency response missions. State and local governments are soliciting pharmaceuticals, over-the-counter products, and drug deactivation systems through this code to stock community health facilities, support pharmacy benefit programs, and maintain emergency response inventories. The issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances representing multiple states. Seminole County, Florida, for instance, is procuring naloxone and safe drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing framework contracts for generic pharmaceuticals and OTC products across participating state and local jurisdictions including Oregon.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs before launching a formal RFP. MMCAP issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and performance beginning July 1, 2026; awarded vendors must work through three authorized wholesalers and comply with cGMP, DSCSA, and FDA requirements, maintaining commercial general liability insurance of at least $5,000,000 per occurrence.